Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

The response rate was higher in those with a KRAS mutation at 44%, compared to 17% in KRAS wild-type patients.

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...

Verastem (VSTM) updated investors on their RAMP programs. Read more to see why I am sticking to the sidelines with my dormant position at this time.

Find the latest Verastem, Inc. (VSTM) stock quote, history, news and other vital information to help you with your stock trading and investing.

Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic ...

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer ...

Verastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular ...

Verastem (VSTM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Verastem Inc. Annual stock financials by MarketWatch. View the latest VSTM financial statements, income statements and financial ratios.

Analysts have provided the following ratings for Verastem (NASDAQ:VSTM) within the last quarter: These 6 analysts have an average price target of $32.67 versus the current price of Verastem at $8. ...